WO2004097422A3 - Diagnostic et traitement de maladies associees au recepteur de la calcitonine (calcr) - Google Patents

Diagnostic et traitement de maladies associees au recepteur de la calcitonine (calcr) Download PDF

Info

Publication number
WO2004097422A3
WO2004097422A3 PCT/EP2004/004102 EP2004004102W WO2004097422A3 WO 2004097422 A3 WO2004097422 A3 WO 2004097422A3 EP 2004004102 W EP2004004102 W EP 2004004102W WO 2004097422 A3 WO2004097422 A3 WO 2004097422A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
calcr
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2004/004102
Other languages
English (en)
Other versions
WO2004097422A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2004097422A2 publication Critical patent/WO2004097422A2/fr
Publication of WO2004097422A3 publication Critical patent/WO2004097422A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un récepteur de la calcitonine (CALCR) associé à des troubles cardio-vasculaires, des maladies gastro-intestinales et hépatiques, des troubles hématologiques, des manifestations cancéreuses, des maladies respiratoires , des troubles neurologiques et des troubles urologiques. Cette invention concerne également des analyses permettant d'identifier des composés utiles pour le traitement ou la prévention des pathologies et troubles susmentionnés. L'invention concerne enfin des composés qui se lient avec CALCR et/ou qui en déclenchent ou en inhibent l'activité ainsi que des compositions pharmaceutiques renfermant ces composés.
PCT/EP2004/004102 2003-04-30 2004-04-17 Diagnostic et traitement de maladies associees au recepteur de la calcitonine (calcr) WO2004097422A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009698 2003-04-30
EP03009698.6 2003-04-30

Publications (2)

Publication Number Publication Date
WO2004097422A2 WO2004097422A2 (fr) 2004-11-11
WO2004097422A3 true WO2004097422A3 (fr) 2004-12-02

Family

ID=33395776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004102 WO2004097422A2 (fr) 2003-04-30 2004-04-17 Diagnostic et traitement de maladies associees au recepteur de la calcitonine (calcr)

Country Status (1)

Country Link
WO (1) WO2004097422A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203747B1 (fr) 2007-09-28 2016-11-30 Welcome Receptor Antibodies PTY LTD Anticorps contre calcitonine
WO2022040035A1 (fr) 2020-08-15 2022-02-24 Regeneron Pharmaceuticals, Inc. Traitement de l'obésité chez des sujets ayant des molécules d'acide nucléique variantes codant pour le récepteur de la calcitonine (calcr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010149A1 (fr) * 1991-11-15 1993-05-27 The General Hospital Corporation Recepteurs de calcinotonine mammifere recombines et leurs emplois
WO1994008006A1 (fr) * 1992-09-30 1994-04-14 Zymogenetics, Inc. Recepteur de la calcitonine humaine
WO1998021242A1 (fr) * 1996-11-15 1998-05-22 Human Genome Sciences, Inc. Recepteur de la calcitonine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010149A1 (fr) * 1991-11-15 1993-05-27 The General Hospital Corporation Recepteurs de calcinotonine mammifere recombines et leurs emplois
WO1994008006A1 (fr) * 1992-09-30 1994-04-14 Zymogenetics, Inc. Recepteur de la calcitonine humaine
WO1998021242A1 (fr) * 1996-11-15 1998-05-22 Human Genome Sciences, Inc. Recepteur de la calcitonine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PURDUE B W ET AL: "Molecular pharmacology of the calcitonin receptor", RECEPTORS AND CHANNELS 2002 UNITED KINGDOM, vol. 8, no. 3-4, 2002, pages 243 - 255, XP008035445, ISSN: 1060-6823 *

Also Published As

Publication number Publication date
WO2004097422A2 (fr) 2004-11-11

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2004097421A3 (fr) Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
WO2005095973A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
WO2004080373A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g
WO2005106489A3 (fr) Diagnostics et therapies s'appliquant a des maladies associees aux recepteurs 5 des chimiokines c-c (ccr5)
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2004099782A3 (fr) Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2004097422A3 (fr) Diagnostic et traitement de maladies associees au recepteur de la calcitonine (calcr)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2004104574A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 7 (ccr7)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2004099783A3 (fr) Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g
WO2005108998A3 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3)
WO2005040824A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 24 couple a la proteine g (gpr24)
WO2005003762A3 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 2 couple a la proteine g specifique aux neurones sensoriels (snsr2)
WO2004082572A3 (fr) Diagnostics et therapies pour les maladies associees au recepteur 87 couple a la proteine g (gpr87)
WO2005040790A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75)
WO2005114209A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 2 specifique du recepteur couple a une proteine g (grk2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase